The e4Risk® is a non-genetic, cost-effective, and highly reliable method to detect the presence of the ApoE4 protein in human blood plasma using high-throughput chemical analysis.
This is achieved using a turbidimetry-based assay with excellent performance in the context of the hospital/clinical settings (100% sensitivity and 99% specificity).
CE Marking. The process of obtaining the FDA approval for the e4Risk® is currently ongoing.
*Test based on patent nº EP 3274725 (European patent granted): “Method for apolipoprotein detection”
If you have any questions or comments, we will be pleased to attend you
If you have any questions or comments,
we will be pleased to attend you